Slimnica Gintermuiza VSIA
- Address
- Filozofu Iela 69, 3008 Jelgava, Latvia
Psychiatry and Psychology at Slimnica Gintermuiza VSIA
Clinical research here focuses on mental disorders, with a strong emphasis on Major Depressive Disorder. The studies are designed to better understand how an added treatment may help reduce depressive symptoms and support people living with persistent depression.
- Evaluating whether a new adjunctive therapy can improve symptoms of Major Depressive Disorder
- Assessing the long-term safety and tolerability of treatment in adults with depression
This research at the Jelgava site in Latvia is centered on improving treatment effectiveness and confirming that care options remain safe and suitable over time.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Neurocrine Biosciences Inc.2active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Neurocrine Biosciences Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 80 other sites in Latvia
Therapeutic Area Benchmark — Latvia
Select a therapeutic area to compare against other sites in Latvia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Latvia
Market Share
Country: Latvia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Slimnica Gintermuiza VSIA
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of NBI-1065845 as Adjunctive Therapy in Adults with Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Study | Neurocrine Biosciences Inc. | Phase III | Recruiting | Aug 2025 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE | 2 | Unknown | 2025-08-28 | 2025-10-07 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.